Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; Botulism Antitoxin Heptavalent for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Trobigard, an atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Emergent BioSolutions Inc.

In a report released yesterday, from Shore Capital reiterated a Hold rating on boohoo group Plc. The company’s shares closed yesterday at p23.00. C...

boohoo group Plc (DEBS) Gets a Hold from Shore Capital

boohoo group Plc ( ($GB:DEBS) ) has issued an announcement. Debenhams Group has launched its 2025 Save As You Earn (SAYE) share scheme, granting op...

Debenhams Group Grants 2025 SAYE Options to 211 Employees Without Dilution to Shareholders

Emergent Biosolutions ( ($EBS) ) has issued an update. Emergent BioSolutions announced on January 12, 2026, that it voluntarily prepaid $100 millio...

Market Cap	$537.80M	P/E Ratio	NaN
52W High	$14.06	52W Low	$4.02
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	-41.5%	52W Position	73.7%
Overall Score	46	Value Score	60
Quality Score	44	Technical Score	36

EPS Current Est	$NA	EPS Next Est	$NA
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	EBS	$11.42	-2.52%	346.05K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	EBS	$11.42	-2.5%	346.05K
3
4
5
6

EBS

EBS

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Emergent BioSolutions Inc. Data in Excel

Get Emergent BioSolutions Inc. Data in Excel